GlassScriptPhysician profile
Janeen E White
NPI 1861910655
$4,258.63
in general payments reported to CMS, 2019-2025
20 companies · $2,209 in 2025
The $2,209 reported for 2025 was more than what 94% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $202 · 2023: $98.37 · 2024: $1,750 · 2025: $2,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,658 · Travel and Lodging: $319 · Education: $79.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,658.34 |
| Travel and Lodging | $318.81 |
| Education | $79.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $923.89 | 2022-2025 | Tezspire, Airsupra, Breztri |
| Inspire Medical Systems, INC. | $629.06 | 2022-2025 | Inspire |
| Glaxosmithkline, LLC. | $618.56 | 2024-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $409.25 | 2023-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $387.25 | 2024-2025 | Glassia |
| Amgen INC. | $249.62 | 2024-2025 | Tezspire |
| Insmed, INC. | $203.75 | 2025 | Arikayce, Brinsupri |
| Verona Pharma, INC. | $148.28 | 2025 | Ohtuvayre |
| Grifols USA, LLC | $140.39 | 2025 | Prolastin-C Liquid |
| Dexcom, INC. | $114.30 | 2024 | Dexcom G7 Gss (161) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.67 | 2025 | Ofev, Jascayd |
| Mylan Specialty L.P. | $79.46 | 2024 | Yupelri |
| Baxter Healthcare | $68.52 | 2025 | |
| Genzyme Corporation | $63.31 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $29.60 | 2025 | Winrevair |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $21.81 | 2023 | |
| Abbvie INC. | $21.41 | 2025 | |
| United Therapeutics Corporation | $16.37 | 2024 | |
| Lilly USA, LLC | $16.26 | 2025 | Zepbound |
| Viatris Specialty LLC | $15.87 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janeen White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.